Scutellaria baicalensis decreases ritonavir-induced nausea

被引：14

作者：

Aung H. ^{[1
,2
]}

Mehendale S. ^{[1
,2
]}

Chang W.-T. ^{[1
,2
]}

Wang C.-Z. ^{[1
,2
]}

Xie J.-T. ^{[1
,2
]}

Yuan C.-S. ^{[1
,2
,3
]}

机构：

[1] Tang Center for Herbal Medicine Research, Pritzker School of Medicine, The University of Chicago, Chicago

[2] Department of Anesthesia, Pritzker School of Medicine, The University of Chicago, Chicago

[3] Committee on Clinical Pharmacology and Pharmacogenomics, Pritzker School of Medicine, The University of Chicago, Chicago

来源：

AIDS Research and Therapy | / 2卷 / 1期

关键词：

Kaolin; Ritonavir; Improve Life Expectancy; Scutellaria Baicalensis; Porcine Carotid Artery;

D O I：

10.1186/1742-6405-2-12

中图分类号：

学科分类号：

摘要：

Background: Protease inhibitors, particularly ritonavir, causes significant gastrointestinal disturbances such as nausea, even at low doses. This ritonavir-induced nausea could be related to its oxidative stress in the gut. Alleviation of drug-induced nausea is important in effectively increasing patients' compliance and improving their quality of life. Conventional anti-emetic drugs can only partially abate the symptoms in these patients, and their cost has also been a concern. Rats respond to nausea-producing emetic stimuli by increasing consumption of non-nutritive substances like kaolin or clay, a phenomenon known as pica. In this study, we used this rat pica model to evaluate the effects of Scutellaria baicalensis, a commonly used oriental herbal medicine, on ritonavir-induced nausea. Results: Rats treated with 20 mg/kg ritonavir significant caused increases of kaolin consumption at 24 to 48 hr (P < 0.01). Pretreatment with 0.3 and 3 mg/kg Scutellaria baicalensis extract significantly decreased ritonavir-induced kaolin intake in a dose-related manner (P < 0.01). Compared to vehicle treatment, the extract completely prevented ritonavir-incluced kaolin consumption at dose 3 mg/kg. The area under the curves (AUC) for kaolin intake from time 0 to 120 hr for vehicle only, ritonavir only, SbE 0.3 mg/kg plus ritonavir, and SbE 3 mg/kg plus ritonavir were 27.3 g·hr, 146.7 g·hr, 123.2 g·hr, and 327 g·hr, respectively. The reduction in area under the curves of kaolin intake from time 0 to 120 hr between ritonavir only and SbE 0.3 mg/kg plus ritonavir, ritonavir only and SbE 3 mg/kg plus ritonavir were 16.0% and 77.7%, respectively. Conclusion: Scutellaria baicalensis significantly attenuated ritonavir-induced pica, and demonstrated a potential in treating ritonavir-induced nausea. © 2005 Aung et al; licensee BioMed Central Ltd.

引用

共 43 条

[1]

Sande M.A., Volberding P.A., The Medical Management of AIDS, (1999)

[2]

Proctor V.E., Tesfa A., Tompkins D.C., Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS, AIDS Patient Care STDS, 13, pp. 535-544, (1999)

[3]

Bartlett J.A., Addressing the challenges of adherence, J Acquir Immune Defic Syndr, 29, SUPPL. 1, (2002)

[4]

Carr A., Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy, Lancet, 360, pp. 81-85, (2002)

[5]

S Hamilton J.D., Hamilton J.D., Hartigan P.M., Simberkoff M.S., Day P.L., Diamond G.R., Hartigan P.M., Simberkoff M.S., Day P.L., Diamond G.R., A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection, N Engl J Med, 326, pp. 437-443, (1992)

[6]

Spruance S.L., Pavia A.T., Mellors J.W., Murphy R., Gathe J.J., Stool E., Jemsek J.G., Dellamonica P., Cross A., Dunkle L., Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial, Ann Intern Med, 126, pp. 355-363, (1997)

[7]

Lichterfeld M., Nischalke H.D., Bergmann F., Wiesel W., Rieke A., Theisen A., Fatkenheuer G., Oette M., Carls H., Fenske S., Nadler M., Knechten H., Wasmuth J.C., Rockstroh J.K., Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy, HIV Med, 3, pp. 37-43, (2002)

[8]

Lalezari J.P., DeJesus E., Northfelt D.W., Richmond G., Wolfe P., Haubrich R., Henry D., Powderly W., Becker S., Thompson M., Valentine F., Wright D., Carlson M., Riddler S., Haas F.F., DeMasi R., Sista P.R., Salgo M., Delehanty J., A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults, Antivir Ther, 8, pp. 279-287, (2003)

[9]

Gartland M., AVANTI 3: A randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients, Antivir Ther, 6, pp. 127-134, (2001)

[10]

Gelmon K., Montaner J.S., Fanning M., Smith J.R., Falutz J., Tsoukas C., Gill J., Wells G., O'Shaughnessy M., Wainberg M., Et al., Nature, time course and dose dependence of zidovudine-related side effects: Results from the Multicenter Canadian Azidothymidine Trial, Aids, 3, pp. 555-561, (1989)

← 1 2 3 4 5 →